JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update

Cogent Biosciences Inc. (NASDAQ:COGT) is 1 of the best emerging exertion stocks to put in. On December 19, JPMorgan raised the firm’s terms people connected Cogent Biosciences to $67 from $65 with an Overweight standing connected the shares. This sentiment was announced arsenic the steadfast broadly updated models successful its smid-cap biotech group.

In different news, connected December 8, Cogent Biosciences announced affirmative top-line results from the registration-directed APEX Part 2 objective trial. The survey evaluated bezuclastinib, which is simply a highly selective and potent KIT D816V inhibitor, successful 81 patients with precocious systemic mastocytosis/AdvSM, a uncommon and assertive humor disorder.  The superior efficacy investigation focused connected 68 evaluable patients, demonstrating an Objective Response Rate/ORR of 57% based connected modified IWG/mIWG criteria, which relationship for the reversal of organ damage. When measured by Pure Pathological Response criteria, the ORR reached 80%.

Bezuclastinib was reported to beryllium well-tolerated, with nary patients discontinuing the survey owed to treatment-related adverse events/TRAEs. The astir communal broadside effects included hairsbreadth colour alteration (30.9%), neutropenia (29.6%), and altered sensation (28.4%). Dose reductions were infrequent, required by lone 14.8% of the participants. These information results are peculiarly notable arsenic the cause is designed to debar the cardinal tense strategy and off-target toxicities, specified arsenic intracranial bleeding, often seen with different treatments successful this class.

This announcement marks the 3rd palmy pivotal proceedings for bezuclastinib successful 2025, pursuing the SUMMIT/NonAdvSM and PEAK/GIST trials. Cogent Biosciences expects to taxable an NDA to the FDA successful H1 2026, with plans for aggregate commercialized launches successful H2 of that year. Detailed information from the APEX proceedings volition beryllium presented astatine a large aesculapian league successful aboriginal 2026.

Cogent Biosciences Inc. (NASDAQ:COGT) is simply a biotechnology institution that develops precision therapies for genetically defined diseases.

While we admit the imaginable of COGT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.